Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 46.6% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (22.4%)
  • Dividend yield for the last twelve months 0.5%
  • Free cash flow yield -0.8% (LTM)
  • Share price is 317.2% higher than minimum and 3.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (60.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $812.3 mln (-0.098% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+0.1%)924.5
year average price 734.56  


year start price 571.28 2023-09-18

min close price 525.19 2023-10-03

max close price 960.02 2024-08-30

current price 923.71 2024-09-16
Common stocks: 903 782 000

Dividend Yield:  0.5%
FCF Yield LTM: -0.8%
EV / LTM EBITDA: 60.3x
EV / EBITDA annualized: 53.3x
Last revenue growth (y/y):  +36.0%
Last growth of EBITDA (y/y):  +57.3%
Historical revenue growth:  +14.5%
Historical growth of EBITDA:  +30.3%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 835 546
Net Debt ($m): 22 389
EV (Enterprise Value): 857 935
EBITDA LTM ($m): 14 235
EV / LTM EBITDA: 60.3x
Price to Book: 61.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-09-13prnewswire.com

FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

2024-09-13fool.com

6 Incredible Reasons to Invest in Eli Lilly

2024-09-12investopedia.com

Eli Lilly Invests $1.8B To Expand Drug Output in Ireland

2024-09-12zacks.com

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

2024-09-12reuters.com

Eli Lilly invests $1.8 bln in Ireland sites to scale up Alzheimer's, obesity drug production

2024-09-12cnbc.com

Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs

2024-09-11247wallst.com

2 Weight Loss Drug Stocks Worth Stashing Away for Years

2024-09-11fool.com

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)

2024-09-11fool.com

Prediction: These 2 Companies Will Split Their Stocks by 2027

2024-09-10prnewswire.com

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data